FIELD: immunology.
SUBSTANCE: antibody to human CD73 or its antigen-binding fragment, a fused protein, polynucleotides, expression vectors, and a host cell are proposed. Besides, methods for producing an antibody to human CD73 or its antigen-binding fragment, a method for producing a fused protein, pharmaceutical compositions, as well as methods for preventing or treating cancer, using an antibody to human CD73, using a fused protein are considered.
EFFECT: present invention can be further used in the therapy of cancer expressing CD73.
35 cl, 3 dwg, 4 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY AGAINST HUMAN FN14 | 2019 |
|
RU2787044C2 |
| METHOD FOR PRODUCING CHEMICAL PRODUCTS OF SUBTLE SYNTHESIS USING CORYNEBACTERIUM SECRETING MODIFIED a-1,6-GLUCOSIDASES | 2018 |
|
RU2763317C2 |
| IMMUNE TOLERANCE INDUCING ANTIBODIES, INDUCED LYMPHOCYTES AND THERAPEUTIC AGENT/METHOD OF CELL THERAPY USING INDUCED LYMPHOCYTES | 2019 |
|
RU2816592C2 |
| KLK5-INHIBITING PEPTIDE | 2019 |
|
RU2826422C2 |
| IMMUNO-INDUCING AGENT | 2016 |
|
RU2744843C2 |
| BISPECIFIC ANTIBODY | 2020 |
|
RU2814713C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMORS | 2017 |
|
RU2755894C2 |
| GENE THERAPY OF HYPOPHOSPHATEMIC DISEASES ASSOCIATED WITH FIBROBLAST GROWTH FACTOR 23 | 2020 |
|
RU2815545C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING MALIGNANT TUMOUR | 2016 |
|
RU2714205C2 |
| HERPES VACCINE | 2019 |
|
RU2731073C1 |
